3rd Pavia international symposium on advanced kidney cancer.

about

3rd Pavia international symposium on advanced kidney cancer.

Item

http://www.wikidata.org/entity/Q53137044

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

3rd Pavia international symposium on advanced kidney cancer.

@en

3rd Pavia international symposium on advanced kidney cancer.

@nl

type

Item

label

3rd Pavia international symposium on advanced kidney cancer.

@en

3rd Pavia international symposium on advanced kidney cancer.

@nl

prefLabel

3rd Pavia international symposium on advanced kidney cancer.

@en

3rd Pavia international symposium on advanced kidney cancer.

@nl

P1476

3rd Pavia international symposium on advanced kidney cancer.

@en

P2093

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

P2860

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

P304

445-453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2012.651461

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Camillo Porta

P577

2012-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22263875

http://www.w3.org/2001/XMLSchema#string